CURRICULUM VITAE

Date of preparation: March 8, 2023

Neil Vasan, MD, PhD

1130 St. Nicholas Avenue, Room 321A
Irving Cancer Research Center
Columbia University School of Medicine
New York, NY 10032
nv2379@cumc.columbia.edu

Place of Birth: Washington DC
Citizenship: USA

ACADEMIC APPOINTMENTS, HOSPITAL APPOINTMENTS, AND OTHER WORK EXPERIENCE

Academic Appointments

07/2021 – present	**Columbia University College of Physicians & Surgeons** Assistant Professor of Medicine	New York, NY
07/2018 – 06/2021	**Weill Cornell Medical College** Instructor in Medicine	New York, NY

Hospital Appointments

07/2021 – present	**New York-Presbyterian Hospital / Columbia University Irving Medical Center**	New York, NY
07/2018 – 06/2021	**Memorial Sloan Kettering Cancer Center** Assistant Attending Physician, Breast Medicine Service	New York, NY

EDUCATION

09/2005 – 06/2013	**Yale University School of Medicine** MD/PhD, May 2004 *PhD in Cell Biology, Structural studies of the GARP tethering complex (2011), Advisor: Karin Reinisch, PhD*	New Haven, CT
08/1995 – 05/1999	**Harvard University and Harvard College** AB/AM in Chemistry, May 2005	Cambridge, MA

TRAINING

09/2019 – 06/2021	**Meyer Cancer Center, Weill Cornell Medical College** Postdoctoral Fellow, Laboratory of Lewis Cantley, PhD	New York, NY
07/2016 – 08/2019	**Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center** Postdoctoral Fellow, Laboratories of José Baselga, MD, PhD and Maurizio Scaltriti, PhD	New York, NY
07/2016 – 06/2017	**Department of Medicine, Memorial Sloan Kettering Cancer Center** Medical Oncology Chief Fellow	New York, NY
07/2015 – 06/2018	**Department of Medicine, Memorial Sloan Kettering Cancer Center** Medical Oncology Fellow	New York, NY
07/2014 – 06/2015	**Department of Medicine, Massachusetts General Hospital** Internal Medicine Resident	Boston, MA
07/2013 – 06/2014	**Department of Medicine, Massachusetts General Hospital** Internal Medicine Intern	Boston, MA

EXPLANATION OF GAPS IN WORK/TRAINING/EDUCATION

Not applicable

LICENSURE AND BOARD CERTIFICATION

LICENSURE

2015 – present New York State Medical License Number 281568-1

BOARD QUALIFICATION

2018 – present Medical Oncology, American Board of Internal Medicine
2017 – present Internal Medicine, American Board of Internal Medicine

HONORS AND AWARDS

2023	Breast Cancer Alliance Young Investigator Award
2022	New York Super Doctors Rising Star 2023
2022	VELOCITY Fellow, CUIMC
2022	Gilead Research Scholar
2022	Louis V. Gerstner Jr. Scholar
2022	ASCI Young Physician-Scientist Award
2022	New York Super Doctors Rising Star 2022
2020	American Association of Cancer Research NextGen Star (8-12 recipients yearly)

2020	FDA-AACR Oncology Educational Fellowship (20 recipients yearly)
2017	Society for Translational Oncology Fellows' Forum
2016	AACR Molecular Biology in Clinical Oncology Workshop
2016	John Mendelsohn Housestaff Teaching Award, MSKCC
2010 – 2012	Associate Faculty Member, Faculty of 1000
2001 – 2005	Harvard College Scholarship and Dean's List
2001 – 2005	Robert C. Byrd Scholarship
2001 – 2005	National Merit Scholar
2001	United State Presidential Scholar (given to top male high school graduate in WV)
2001	Eagle Scout

ACADEMIC SERVICE

02/2023	HICCC Early Career Development Pilot Award Reviewer
11/2022 – present	HICCC Shared Resource Organizing Committee member
01/2022 – present	Columbia Center for Precision Cancer Medicine Monthly Molecular Therapeutics Meeting moderator
05/2020 – 12/2022	PI3K Disease Modeling and Drug Targeting Worldwide Zoom Seminar Co-organizer. *This is an international biweekly series that I co-organized to promote early career researchers in the PI3K field, during the COVID-19 pandemic*
09/2020 – 06/2021	Memorial Sloan Kettering Cancer Center (MSKCC) Grand Rounds Organizing Committee Member
06/2019 – 11/2020	MSKCC Junior Faculty Council member

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

- MEMBERSHIPS AND POSITIONS

03/2021 – present	SWOG Breast Cancer Translational Medicine Working Group member
06/2019 – present	ASCO Membership Advisory Committee Early Career Working Group member
06/2018 – present	ASCO Virtual Mentoring Program member
06/2017 – 05/2018	ASCO Ethics Committee liaison
04/2016 – 03/2019	AACR Associate Member Council member
06/2016 – 05/2018	ASCO Trainee Council member

2021 – present	SWOG
2019 – present	European Society of Medical Oncology
2015 – present	American Association for Cancer Research
2014 – present	American Society of Clinical Oncology
2008 – 2011	American Society for Cell Biology
2005 – 2013	American College of Physicians

- CONSULTATIVE (FEDERAL, STATE, PRIVATE)

2022 – 2026	Oncology Drugs Advisory Committee (ODAC) standing member, U.S. Food and Drug Administration (federal)

2023 – 2025 San Antonio Breast Cancer Symposium Program Planning Committee Member (international)

2022 – 2024 Conquer Cancer-BCRF Young Investigator Award (YIA) & Career Development Award (CDA) for Diversity and Inclusion in Breast Cancer Research Expert Review Panel member (private)

2020 – present Cancer Prevention & Research Institute of Texas (CPRIT) Product Development Review Council member (state)

2020 – 2022 Innovation in Cancer Informatics (ICI) Grant Review Committee member (private)

- JOURNAL REVIEWER

American Journal of Clinical Pathology
Breast Cancer Research
Cancer
Cancer Discovery
Cancer Research Communications
Cell Death and Differentiation
Clinical Breast Cancer
Hematology/Oncology and Stem Cell Therapy
Journal of Clinical Investigation
Journal of Clinical Investigation Insight
Nature Communications
Oncogene
Proceedings of the National Academy of Sciences
Science Advances

- EDITORIAL

2022 Peer reviewer for ESMO Handbook of Targeted Therapies and Precision Oncology
2022 Peer reviewer for ASCO Educational Book
2022 – present Member of ASCO SEP Item Writing Task Force
2021 ASCO Medical Student & Resident Abstract Forum facilitator
2017 – 2018 ASCO University Review Panel member

FELLOWSHIP AND GRANT SUPPORT

- PRESENT SUPPORT

07/2020 – 06/2025 NCI K08 CA245192

mutations in *cis*
Amount: $1,315,170
Role: Principal Investigator

07/2022 – 06/2025 Louis V. Gerstner Jr. Scholar/Internal award

Targeting SHP2 in EGFR+ triple negative breast cancer
Amount: $225,000
Role: Principal Investigator

07/2022 – 06/2024 Gilead Research Scholars
Large-scale functional analysis of PIK3CA variants in cancer
Amount: $130,000
Role: Principal Investigator

07/2022 – 06/2023 Columbia 2022 VELOCITY Cancer Research Awards/Internal award
Large scale functional examination of *PIK3CA* variants and PI3K inhibitor sensitivity in breast cancer
Amount: $100,000
Role: Principal Investigator

03/2023 – 02/2025 Breast Cancer Alliance Young Investigator Award

Amount: $125,000
Role: Principal Investigator

- PAST SUPPORT

10/2019 – 07/2022 Susan G. Komen Career Catalyst Research (CCR) Grant GC235789
Double hit compound PIK3CA mutations in ER+ metastatic breast cancer
Amount: $450,000
Role: Principal Investigator

07/2020 – 06/2021 NCI P50 CA247749
MSK SPORE in Genomic Instability in Breast Cancer (Developmental Research Program)
Amount: $50,000 yearly
Role: Co-Investigator
PI: Simon Powell and Jorge Reis Filho

08/2018 – 07/2020 NCI R21 CA223789
Mechanisms of action dual compound oncogenic PIK3CA mutations
Amount: $105,487
Role: Co-Investigator
PI: Maurizio Scaltriti

07/2018 – 06/2019 American Society of Clinical Oncology Young Investigator Award
Dual compound PIK3CA mutations in the pathogenesis and treatment of metastatic breast cancer
Amount: $50,000
Role: Principal Investigator

07/2018 – 06/2019 Society of Memorial Sloan Kettering Research Grant
Discovery and Validation of Tandem Mutations Driving Cancer
Amount: $50,000
Role: Principal Investigator

06/2018 – 06/2020 Innovations in Cancer Informatics Grant, Brown Performance Group GC240757
Discovery and Validation of Tandem Mutations Driving Cancer
Amount:
Role: Principal Investigator

09/2017 – 08/2018 NIH T32-CA009207
Investigational Cancer Therapeutics Training Program Grant (ICTTP)
Role: Trainee
PI: Mark Kris and Jedd Wolchok

09/2016 – 06/2017 NIH UL1TR00457
Clinical Research Methodology Curriculum (CRMC)
Role: Participant
PI: Dean Bajorin

09/2009 – 08/2012 NIH F30-HL097628-01
Structural Studies of the Exocyst
Role: Principal Investigator

07/2006 – 06/2013 NIH MSTP TG 2T32GM07205
Medical Scientist Training Program (MSTP)
Role: Trainee
PI: James Jamieson

- PENDING SUPPORT

None

EDUCATIONAL CONTRIBUTIONS

- Direct Teaching/Precepting/Supervising

10/2021	Clerkship Supervisor for Columbia University Vagelos College of Physicians and Surgeons (VP&S) first-year medical students, Foundations of Clinical Medicine Clerkship, 2 days/year (3 hours total)
03/2021 – present	Teaching Columbia University Medical Center (CUMC) fellows, ad hoc basis
07/2018 – 06/2021	Teaching Memorial Sloan Kettering Cancer Center (MSKCC) residents as Ward attending, 2 weeks/year
07/2018 – 06/2021	Teaching MSKCC residents and fellows in Outpatient clinic, ad hoc basis
07/2015 – present	Teaching MSKCC residents and fellows in weekly noon conferences, ad hoc basis

- Development of instructional material and curriculum used locally

None

- Advising and Mentorship

07/2022 – present External member of thesis committee for Arpit Dave (lab of Robert Sebra, Mount Sinai School of Medicine)
05/2022 – present Member of thesis committee for Jessica Armand (lab of Hee Won Yang)
01/2022 – present Direct laboratory training and supervising of Allison Kearney (postdoctoral fellow)
10/2021 – present Direct laboratory training and supervising of Hanna Karvonen (postdoctoral fellow)
10/2021 – present Direct laboratory training and supervising of Sophie Abrahamson (Columbia undergraduate student)
10/2021 – present Direct laboratory training and supervising of Maya Schonberg (high school student)
05/2020 – present Direct laboratory training and supervising of Ruchita Rathod (laboratory technician)
06/2017 – 08/2019 Direct laboratory training and supervising of Hong Zhao (laboratory technician, currently laboratory technician). She was a second author on my postdoctoral *Science* paper.
06/2018 – present Direct laboratory training and supervising of Abiha Kazmi (high school student, currently undergraduate student), as a Stand Up to Cancer Emperor Science Award Mentor. She was a co-author on my 2019 *Science* paper and received the Goldwater Scholarship.

- Educational Administration and Leadership

11/2021 – present Interviewer for Columbia MSTP program

- Instructional/Educational Materials used in Print or other Media

10/2021 – present Expert reviewer for breast cancer content on www.survivornet.com, ad hoc basis

- Community Education

10/2021 Bone Metastases. Susan G. Komen Foundation Metastatic Breast Cancer Awareness Day 2021. 30-minute presentation for breast cancer survivors.
10/2021 Essentials in Cardio-Oncology: Anthracycline and HER-2 Targeted Therapy Related Cardiotoxicity. New York-Presbyterian/CUIMC Cardio-Oncology Summit 2021. One hour presentation for cardiologists.
10/2019 Advances in Lobular Breast Cancer. New York Metastatic Breast Cancer Conference, New York, NY. One hour presentation for breast cancer survivors.
4/2019 Advances in Hormone Receptor Positive Breast Cancer. Living Beyond Breast Cancer 2019 Conference on Metastatic Breast Cancer, Philadelphia, PA. One hour presentation for breast cancer survivors.

REPORT OF CLINICAL AND PUBLIC HEALTH ACTIVITIES AND INNOVATIONS

02/2022 – present Inpatient Ward attending for Columbia University Medical Center (CUMC) Oncology Service, 4 weeks/year
09/2021 – present Outpatient medical oncologist with CUMC Breast Oncology group, ½ day weekly
07/2018 – 06/2021 Inpatient Ward attending for Memorial Sloan Kettering Cancer Center (MSKCC) Breast Medicine Service, 2 weeks/year
07/2018 – 06/2021 Outpatient medical oncologist on MSKCC Breast Medicine Service, ½ day weekly

PATENTS & INVENTIONS

- Patents

Vasan N, Baselga J. U.S. Patent Number WO2020041684A1: "Biomarkers for Determining Responsiveness of a Cancer to PI3K Inhibitors," Patent granted February 27, 2020.

PUBLICATIONS

- ORIGINAL, PEER-REVIEWED RESEARCH PUBLICATIONS IN PRINT OR OTHER MEDIA

Sivakumar S, Jin DX, Rathod R, Ross J, Cantley LC, Scaltriti M, Chen J, Hutchinson KE, Wilson TR, Sokol ES*, **Vasan N***. Genetic heterogeneity and tissue-specific patterns of tumors with multiple *PIK3CA* mutations. *Clinical Cancer Research*, 2023 Jan 3:CCR-22-2270.

Johnson JL, Yaron, TM, Huntsman EM, Kerelsky A, Song J, Regev A, Lin TY, Liberatore K, Cizin DM, Cohen BM, **Vasan N**, Ma Y, Krismer K, Robles JT, van de Kooij V, van Vlimmeren AE, Andree-Busch N, Kaufer N, Dorovkov MV, Ryazanov AG, Takagi Y, Kastenhuber ER, Goncalves MD, Elemento O. Taatjes DJ, Maucuer A, Uamashita A, Degterev A, Linding R, Blenis J, Hornbeck PV, Turk BE, Yaffe MB, Cantley LC. A global atlas of substrate specificities for the human serine/threonine kinome. *Nature* 2023 613:759-766.

Lin TY, Ramsamooj S, Liberatore K, Lantier L, **Vasan N**, Karukurichi K, Hwang SK, Kesicki EA, Kastenhuber ER, Wiederhold T, Yaron TM, Zhu M, Ma Y, Paddock MN, Zhang G, Hopkins BD, McGuinness O, Schwartz RE, Cantley LC, Johnson JL, Goncalves MD. Epinephrine inhibits PI3K alpha via the Hippo Kinases.
bioRxiv 2022.07.19.500601; doi: https://doi.org/10.1101/2022.07.19.500601

Ho P, Melms JC, Rogava M, Frangieh CJ, Shah SB, Walsh Z, Kyrysyuk O, Amin AD, Caprio L, Fullerton BT, Soni R, Ager CR, Biermann J, Wang Y, Mu M, Fatima H, Moore EK, **Vasan N**, Bakhoum SF, Reiner SL, Bernatchez C, Mace EM, Wucherpfennig KW, Schandendorf D, Schwarz GK, Izar B. The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity.
bioRxiv 2022.03.21.485049; doi: https://doi.org/10.1101/2022.03.21.485049

Taylor SR, Ramsamooj S, Liang RJ, Katti A, Pozovskiy R, **Vasan N**, Hwang SK, Nahiyaan N, Francoeur NJ, Schatoff EM, Johnson JL, Shah MA, Dannenberg AJ, Sebra RP, Dow LE, Cantley LC, Kyu KY, Goncalves MD. Dietary fructose improves intestinal cell survival and nutrient absorption. *Nature* 2021 597:263-267.

Blow T, Hyde PN, Falcone JN, Neinstein A, **Vasan N**, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. *Integr Cancer Ther* 2021 20: 15347354211032283.

Li J, Duran MA, Dhanota N, Chatila WK, Kwon J, Sriram RK, Humphries MP, Salto-Tellez M, James JA, Hanna MG, Melms JC, Vallabhaneni S, Litchfield K, Martin ML, Dorsaint P, Cavallo JA, Li P, Pauli C, Gottesdiener L, DiPardo BJ, Hollmann TJ, Merghoub T, Wen HY, Reis-Filho JS, Riaz N, Dr. Kalbasi A, **Vasan N**, Wolchok JD, Elemento O, Swanton C, Shoushtari AN, Bettigole SE, Powell SN, Usaite I, Biswas D, Li HW, Su SM, Bareja R, Parkes EE, Izar B, Bakhoum S. Metastasis and immune evasion from extracellular cGAMP hydrolysis. *Cancer Discov*, 2021 11:1212-1227.

Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, **Vasan N**, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. *Cancer Discov* 2020 11:126-141.

Gorelick A, Sanchez-Rivera F, Cai Y, Bielski C, Biederstedt E, Jonsson P, Richards A, **Vasan N**, Penson A, Friedman N, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe S, Reznik E, Taylor B. Phase and context shape the function of composite oncogenic mutations. *Nature* 2020

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, **Vasan N**, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in *PTEN* and *ESR1* promote clinical resistance to alpelisib plus aromatase inhibitors. *Nat Cancer* 2020 1:382-393.

Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M*, Baselga J*. Double *PIK3CA* mutations in *cis* increase oncogenicity and sensitivity to PI3Kα inhibitors. *Science* 2019 366:714-723.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, **Vasan N**, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB*, Taylor BS*, Baselga J*. The genomic landscape of endocrine resistant advanced breast cancers. *Cancer Cell* 2018 34:427-438.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted Next Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. *Oncologist* 2014 19:453-458.

Vasan N, Hutagalung A, Novick P, and Reinisch KM. Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of the Golgi-associated retrograde protein (GARP) complex to a family of tethering complexes. *PNAS* 2010 107:14176-81.

- OTHER PEER-REVIEWED PUBLICATIONS IN PRINT OR OTHER MEDIA

None

- REVIEWS, CHAPTERS, MONOGRAPHS, EDITORIALS

Vasan N and Cantley LC. At a crossroad: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. *Nat Rev Clin Oncol* 2022 19:471-485.

Mullangi S and **Vasan N.** Genomic Characterization of De Novo Metastatic Breast Cancer. *Clin Breast Cancer* 2022 22:98-102.

Castel P, Toska E, **Vasan N**, Cocco E, Scaltriti M. José Baselga (1959-2021). *Cancer Cell* 2021 39:581-582.

Vasan N, Hyman DM, and Baselga, J. A view on drug resistance in cancer. *Nature* 2019 575:299-309.

Vasan N*, Toska E*, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. *Ann Oncol* 2019 30:3-11.

Vasan N, Boyer JL, and Herbst RS. A Ras renaissance: emerging targeted therapies for KRas-mutated non-small cell lung cancer. *Clin Cancer Res* 2014 20:3921-3930.

- BOOKS/TEXTBOOKS FOR MEDICAL OR SCIENTIFIC COMMUNITY

Choudhury N, Muciano-Goroff YR, Drilon A*, **Vasan N***. Pocket Oncology, 3rd edition. Lippincott, Williams, & Wilkins, 2022. Advisor.

Vasan N*, Carlo M*, Drilon A, Postow M. Pocket Oncology, 2nd edition. Lippincott, Williams, & Wilkins, 2018. Editor and Author.

Bhushan V, Le T, **Vasan, N**, Tolles J. First Aid for the USMLE Step 1 2010. McGraw-Hill Company, 2010. Editor.

Bhushan V, Le T, Grimm L, **Vasan N**. First Aid for the USMLE Step 1 2009. McGraw-Hill Company, 2009. Editor.

- MEETINGS/INVITED ORAL AND POSTER PRESENTATIONS

12/2021	Genomic landscape of HER2-negative advanced or metastatic breast cancer with *PIK3CA* gain-of-function mutations. San Antonio Breast Cancer Symposium 2021. Poster presentation.
09/2020	A pan-cancer analysis of double *PIK3CA* mutations. ESMO 2020 Virtual Congress. Poster presentation. Abstract published in *Annals of Oncology*.
06/2020	Identifying novel ways to overcome or prevent drug resistance. AACR 2020 Virtual Conference. Invited oral presentation. Abstract published in *Cancer Research.*
06/2020	Double *PIK3CA* mutations in *cis* enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. AACR 2020 Virtual Conference. Invited oral presentation. Abstract published in *Cancer Research.*
12/2019	Double *PIK3CA* mutations in *cis* enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. San Antonio Breast Cancer Symposium 2019. San Antonio, TX. Poster presentation. Abstract published in *Cancer Research.*

05/2019 Double *PIK3CA* mutations in *cis* enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. ESMO Breast Cancer 2019. Berlin, Germany. Oral presentation. Abstract published in *Annals of Oncology*.

04/2019 Double *PIK3CA* mutations in *cis* enhance PI3K oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. AACR Annual Meeting. Atlanta, GA. Poster presentation. Abstract published in *Cancer Research.*

03/2019 Double *PIK3CA* mutations in *cis* enhance PI3K oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. The Tumour Cell: Plasticity, Progression and Therapy. New York, NY. Poster presentation.

12/2018 Compound *PIK3CA* mutations support a mutational dose response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer. AACR Targeting PI3K/mTOR Signaling. Boston, MA. Poster presentation.

06/2017 On the Shoulders of Giants. American Society of Clinical Oncology. Chicago, IL. Invited oral presentation.

12/2010 Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of the GARP complex to a family of tethering complexes. American Society for Cell Biology annual meeting, Philadelphia, PA, 2010. Oral presentation.

10/2010 Structural studies of the GARP tethering complex. American Society for Biochemistry and Molecular Biology Special Symposium on the Secretory and Endocytic Pathways, Tahoe City, CA, 2010. Poster presentation.

07/2010 Structural studies of the GARP tethering complex. National MD/PhD Student Conference, Keystone, CO, 2010. Poster presentation.

- CASE REPORTS

Blow T, Hyde PN, Falcone JN, Neinstein A, **Vasan N,** Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. *Integr Cancer Ther* 2021 20: 15347354211032283.

Vasan N, Braghiroli MI, Shoushtari AN, *et al.* An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. *Journal of Gastrointestinal Oncology* 2017 8:596-602.

Vasan N, Saglan O, Killelea BK. Metastatic leiomyosarcoma presenting as bilateral, multifocal breast masses. *BMJ Case Reports* 2012 doi:10.1136/bcr-2012-007188.

- LETTERS TO THE EDITOR

None

- OTHER MEDIA

Bio Bytes 29: Kinase Proteomics and Oncology with Neil Vasan. Columbia University Bio Bytes Podcast. April 27, 2022. https://anchor.fm/biobytes

- THESIS

Vasan N. Structural studies of the GARP tethering complex. Yale University School of Medicine, 2011.

- OTHER NON-PEER REVIEWED PUBLICATIONS IN PRINT OR OTHER MEDIA

Vasan N and Dickler MN State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer. *AJHO* 2017 13:16-22.

- NON-AUTHORED PUBLICATIONS

My postdoctoral paper (Vasan et al, *Science* 2019) has been featured in the following publications:

1) Perspective by Dr. Alex Toker (*Science* 2019, 366:685-686)
2) Online Research Watch in *Cancer Discovery* (DOI: 10.1158/2159-8290.CD-RW2019-172)
3) News in Depth in *Cancer Discovery* (DOI: 10.1158/2159-8290.CD-ND2020-013)
4) In The Literature in *ESMO Open* (DOI: 10.1136/esmoopen-2020-00680)
5) Genomeweb.com (www.genomeweb.com/cancer/double-mutations-pik3ca-gene-increase-patient-sensitivity-targeted-therapies-study-finds#.Xp79Wy-z2u5)
6) "Your Drug Mileage May Vary: The PIK3CA Double Mutation Story" by Liz Tseng in *Medium* (https://medium.com/pacbio/your-drug-mileage-may-vary-the-pik3ca-double-mutation-story-83f41f6a4f61)

The Democratization of Precision Medicine: A Clinician's Perspective on the Future of Oncology Care - Q&A With Neil Vasan, MD, PhD. *AJMC* 2020.

INVITED AND/OR PEER-SELECTED PRESENTATIONS AT REGIONAL, NATIONAL OR INTERNATIONAL LEVELS:

12/2022	PI3K/AKT Pathway Inhibition. Therapeutic Approaches for HR+ / HER2- Breast Cancer. Spotlight Poster Discussion Session. San Antonio Breast Cancer Symposium. Invited speaker.
11/2022	*PIK3CA* mutations in breast cancer: sequence, structure, function, and inhibition. Komen Breast Cancer Forum seminar series. University of Texas Southwestern Medical Center. Invited speaker.
02/2022	FDA Oncology Center of Excellence (OCE) Clinical Rounds. Invited speaker.
03/2021	FDA Oncology Center of Excellence Minisymposium on Emerging Biomarkers in Breast Cancer—Looking Beyond ER, PR, and HER2. Invited organizer and panelist.
10/2020	Oncogene additivity in the PI3K pathway. 8th Annual Cancer Research and Oncology Virtual Event. Invited speaker.
09/2020	Oncogene additivity in the PI3K pathway. Women's Malignancies Branch seminar, National Cancer Institute. Invited seminar speaker.
02/2018	Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in

metastatic breast cancer. Peninsula Regional Medical Center, Salisbury, MD. Invited grand rounds speaker.

01/2018 Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Grand Rounds, Maimonides Cancer Center, Brooklyn, NY. Invited grand rounds speaker.

01/2018 Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Grand Rounds, John Theurer Cancer Center, Hackensack, NJ. Invited grand rounds speaker.

07/2016 Applying for Fellowship…What Do I Need to Know? *NEJM* Resident 360. Invited moderator.

06/2016 Physicians Learning and Teaching in Oncology (PLATO) 5th Annual Fellows Forum in Breast Oncology. Chicago, IL. Invited speaker.